Background： Although emerging evidence points to benefits from Tai Chi Chuan （TCC） in improving immune system function, its effects on cellular immune responses remain under-studied. The objective of this study was...Background： Although emerging evidence points to benefits from Tai Chi Chuan （TCC） in improving immune system function, its effects on cellular immune responses remain under-studied. The objective of this study was to evaluate the effects of TCC training on cellular immunity in non-small cell lung cancer patients. Methods： A 2-group randomized trial design in which post-surgical, non-small cell lung cancer survivors were randomly assigned to a TCC training group （n = 16） or a control group （n = 16）. The participants in the TCC group completed a 16-week intervention. The main immune response outcome measures assayed included the ratio of T-helper cells/T-suppressor cells （CD4＋：CD8＋ ratio） and complement regulatory proteins status （CRPs; CD55 and CD59）. Using repeated measures ANOVA, the data were analyzed for the participants who completed the study （n = 27）. Results： At 16 weeks, the TCC participants showed a significantly lower increment in the expression of CD55 （p 〈 0.05） as compared to the control group. No significant between-group differences were found in the CD4＋：CD8＋ ratio or CD59 expression. There were also no significant correlations among the changes in CRPs or T lymphocyte subpopulations, either. Conclusion： A 16-week TCC intervention caused no alterations in CD4＋：CD8＋ ratio, but significantly attenuated CD55 expression among post- surgical non-small cell lung cancer survivors.展开更多
基金supported by the National Natural Science Foundation of China(No.30840046)
文摘Background： Although emerging evidence points to benefits from Tai Chi Chuan （TCC） in improving immune system function, its effects on cellular immune responses remain under-studied. The objective of this study was to evaluate the effects of TCC training on cellular immunity in non-small cell lung cancer patients. Methods： A 2-group randomized trial design in which post-surgical, non-small cell lung cancer survivors were randomly assigned to a TCC training group （n = 16） or a control group （n = 16）. The participants in the TCC group completed a 16-week intervention. The main immune response outcome measures assayed included the ratio of T-helper cells/T-suppressor cells （CD4＋：CD8＋ ratio） and complement regulatory proteins status （CRPs; CD55 and CD59）. Using repeated measures ANOVA, the data were analyzed for the participants who completed the study （n = 27）. Results： At 16 weeks, the TCC participants showed a significantly lower increment in the expression of CD55 （p 〈 0.05） as compared to the control group. No significant between-group differences were found in the CD4＋：CD8＋ ratio or CD59 expression. There were also no significant correlations among the changes in CRPs or T lymphocyte subpopulations, either. Conclusion： A 16-week TCC intervention caused no alterations in CD4＋：CD8＋ ratio, but significantly attenuated CD55 expression among post- surgical non-small cell lung cancer survivors.
